Federal National Mortgage Association
Change company Symbol lookup
Select an option...
FNMA Federal National Mortgage Association
CPKF Chesapeake Financial Shares Inc
AGNC Agnc Investment Corp
BYND Beyond Meat Inc
NDENF Central African Gold Inc
HD Home Depot Inc
ACPS AC Partners Inc
FONR Fonar Corp
WBRRFX BlackRock Russell 2000 Growth Index Fund
WSM Williams-Sonoma Inc

Financials : Thrifts & Mortgage Finance | Small Cap Value
Company profile

Federal National Mortgage Association is a government-sponsored enterprise chartered by Congress. The Company serves as a source of liquidity for purchases of homes and financing of multifamily rental housing, as well as for refinancing existing mortgages. It operates through two segments: Single-Family and Multifamily. Its Single-Family and Multifamily segments engage in business activities that provide liquidity to the mortgage market and manage the availability and affordability of housing in the United States. The Single-Family segment operates in the secondary mortgage market relating to loans secured by properties containing four or fewer residential dwelling units. The Multifamily segment operates in the secondary mortgage market relating primarily to loans secured by properties containing five or more residential units. The Company funds its business primarily through the issuance of short-term and long-term debt securities in the domestic and international capital markets.

Closing Price
Day's Change
0.03 (1.52%)
B/A Size
Day's High
Day's Low

10-day average volume:

Interventional Neurology Devices And Equipment Global Market Report 2020-30: Covid 19 Impact and Recovery

10:29 am ET September 16, 2020 (Globe Newswire) Print

Reportlinker.com announces the release of the report "Interventional Neurology Devices And Equipment Global Market Report 2020-30: Covid 19 Impact and Recovery" - https://www.reportlinker.com/p05967837/?utm_source=GNW

3 billion in 2019 to $1.9 billion in 2020 at a compound annual growth rate (CAGR) of -17.6%. The decline is mainly because of worldwide supply and demand mismatches of resources due to the COVID-19 outbreak. There is an inadequate production of devices used in neurological disease treatment, due to the restrictions imposed by governments of various countries to shutdown factories or function with minimal staffing in order to contain the spread of virus and keep the staff safe. Additionally, the restrictions on non-essential medical services also hampered the market growth. The market is then expected to recover and grow at a CAGR of 8.2% from 2021 and reach $3.1 billion in 2023.

The interventional neurology devices and equipment market consists of sales of interventional neurology devices which are used to treat neurovascular diseases such as aneurysms, arteriovenous malformations, cavernous malformations and stroke. Based on the product type, these devices are classified into aneurysm coiling & embolization devices, support devices, cerebral balloon angioplasty & stenting systems and neurothrombectomy devices. Interventional Neurology devices are also known as Neurovascular devices.

In 2018, North America was the largest region in the interventional neurology devices and equipment. During the forecast period, Asia Pacific is forecasted to register the highest CAGR.

The United States Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) presides over the regulation and approval of medical devices in the USA. Within CDRH, the Division of Neurological and Physical Medicine Devices reviews medical technologies that interface with the central and peripheral nervous system (neurotechnologies), including neurointerventional medical devices that are used in the treatment of stroke. Also, the division of Neurological and Physical Medicine Devices (DNPMD) serves as the primary point of review at the FDA for regulatory submissions involving medical device neurotechnologies. Although the process of approval is strenuous and the time taken is too long, the devices approved by FDA have had a major impact on the markets and the products approved by FDA are successful. FDA has been actively approving devices in the interventional neurosurgery device division which has boosted the market's growth. For example, approval of Stryker's Neuroform Atlas Stent System, De Novo clearance for Nerivio Migra and Pipeline Flex embolization by Medtronic are the recent approvals made by FDA which enhances the market's growth.

Strict regulatory policies by the US FDA for the approval of Interventional Neurological Devices will hinder the interventional neurological devices market growth. FDA gives approval for the devices based on the class of the devices. Most of the devices under Interventional Neurological Devices are classified under the class 3 devices. Class 3 devices required to undergo a lot of approvals from the regulatory bodies which is a time consuming process. For example, the approval for the class 3 devices may take more than 36 months, thereby increasing the overall cost of product development, impacting the market negatively.

Stryker Inc.'s latest technological development Neuroform Atlas Stent System is expected to provide significant results to treat brain aneurysms with embolic coils. The introduction of such technologies would drive the interventional neurological device market in the future. The Atlas stent system provides great support during the coiling procedures and it has been designed s to provide the coil support and wall apposition needed to perform effective stent-assisted coiling procedure. Neuroform Atlas has enhanced stent conformability, a low-profile delivery system and high deployment accuracy even in distal anatomy makes it the latest choice of the neuro-surgeons, thereby steering the market.

Increase in the patient population with the neurological disorders is driving the Interventional neurology devices market. Neural disorders like Alzheimer disease, cerebrovascular diseases including stroke, migraine and other headache disorders are on the rise. The rapid increase in the geriatric population, high-stress levels in young individuals and head injuries due to accidents are the main reasons for neural disorders. For example, according to the Brain Aneurysm Foundation, it is estimated that in United States, 6 million people suffer from unruptured brain aneurysm. Also, according to World Health Organization, more than 50 million have epilepsy and over 47 million have dementia. Hence, the rapid increase in the incidence of the neurological disorders is slated to boost the market in the forecast period.

Read the full report: https://www.reportlinker.com/p05967837/?utm_source=GNW

About Reportlinker

ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.


Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001


comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.